Most FDA scientific staff opposed a White House-bound plan easing access to injectable peptides such as BPC-157, sources say, as the policy moves toward publication.
FDA scientists opposed easier access to unproven peptides pushed by Kennedy
Most FDA scientific staff opposed a White House-bound plan easing access to injectable peptides such as BPC-157, sources say, as the policy moves toward publication.
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.